Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Agricultural Inputs

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.

Revenue projections:

Revenue projections for BAYERCROP
Revenue projections for BAYERCROP

Revenues for BAYERCROP are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 2.295000
forwardPE 26.364504
debtToEquity 3.266000
earningsGrowth 0.120000
revenueGrowth -0.106000
grossMargins 0.384420
operatingMargins 0.122890
trailingEps 135.300000
forwardEps 0.000000

Bayer CropScience Limited's current ratio being 2.295 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Bayer CropScience Limited can meet its financial obligations with ease.
With BAYERCROP's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
BAYERCROP's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.
BAYERCROP's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.

Price projections:

Price projections for BAYERCROP
Price projections for BAYERCROP

Price projections for Bayer CropScience Limited have been gradually reduced, reflecting growing uncertainty about the company's future performance. The downward revisions indicate analysts are lowering their expectations for Bayer CropScience Limited's market trajectory.

Recommendation changes over time:

Recommendations trend for BAYERCROP
Recommendations trend for BAYERCROP


Analysts have shown a buy bias for BAYERCROP, marking it as a favorable investment option. This could inspire investors to see BAYERCROP as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.